Arterial hypertension and cancer
- PMID: 23784914
- DOI: 10.1002/ijc.28334
Arterial hypertension and cancer
Abstract
Arterial hypertension and cancer are two of the most important causes of mortality in the world; correlations between these two clinical entities are complex and various. Cancer therapy using old (e.g., mitotic spindle poisons) as well as new (e.g., monoclonal antibody) drugs may cause arterial hypertension through different mechanisms; sometimes the increase of blood pressure levels may be responsible for chemotherapy withdrawal. Among newer cancer therapies, drugs interacting with the VEGF (vascular endothelial growth factors) pathways are the most frequently involved in hypertension development. However, many retrospective studies have suggested a relationship between antihypertensive treatment and risk of cancer, raising vast public concern. The purposes of this brief review have then been to analyse the role of chemotherapy in the pathogenesis of hypertension, to summarize the general rules of arterial hypertension management in this field and finally to evaluate the effects of antihypertensive therapy on cancer disease.
Keywords: anti VEGF drugs; antihypertensive therapies; arterial hypertension; cancer therapies.
© 2013 UICC.
Similar articles
-
Arterial hypertension in cancer: The elephant in the room.Int J Cardiol. 2019 Apr 15;281:133-139. doi: 10.1016/j.ijcard.2019.01.082. Epub 2019 Jan 28. Int J Cardiol. 2019. PMID: 30718135 Review.
-
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.Cancer. 2015 Jan 15;121(2):311-9. doi: 10.1002/cncr.28972. Epub 2014 Sep 18. Cancer. 2015. PMID: 25236375 Free PMC article.
-
Hypertension management in the era of targeted therapies for cancer.Oncology (Williston Park). 2009 Apr;23(4 Suppl Nurse Ed):41-5. Oncology (Williston Park). 2009. PMID: 19856597 No abstract available.
-
Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.Am J Hypertens. 2014 Jan;27(1):3-13. doi: 10.1093/ajh/hpt201. Epub 2013 Oct 29. Am J Hypertens. 2014. PMID: 24168915 Review.
-
Arterial hypertension in patients under antineoplastic therapy: a systematic review.J Hypertens. 2019 May;37(5):884-901. doi: 10.1097/HJH.0000000000002006. J Hypertens. 2019. PMID: 30624368
Cited by
-
Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.Int J Clin Oncol. 2023 Oct;28(10):1259-1297. doi: 10.1007/s10147-023-02372-4. Epub 2023 Jun 29. Int J Clin Oncol. 2023. PMID: 37382749 Review.
-
From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.Antioxid Redox Signal. 2019 Jun 20;30(18):2110-2153. doi: 10.1089/ars.2016.6930. Epub 2017 May 15. Antioxid Redox Signal. 2019. PMID: 28398124 Free PMC article. Review.
-
[Summary of the ESC position paper on cancer treatment and cardiovascular toxicity].Herz. 2016 Dec;41(8):684-689. doi: 10.1007/s00059-016-4493-6. Herz. 2016. PMID: 27830273 Review. German.
-
Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies.Clin Drug Investig. 2017 Feb;37(2):121-134. doi: 10.1007/s40261-016-0460-5. Clin Drug Investig. 2017. PMID: 27638052 Review.
-
Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study.Aging (Albany NY). 2019 Sep 27;11(18):7948-7960. doi: 10.18632/aging.102301. Epub 2019 Sep 27. Aging (Albany NY). 2019. PMID: 31562288 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical